Clinical Trial Update: A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial update announces CTS3497 for MTAP-deficient malignancies including solid tumors and lymphomas, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Solid Tumor

Drugs mentioned

• CTS3497

Snippet

Sponsor: CytosinLab Therapeutics Co., Ltd. | Conditions: Solid Tumor, Lymphoma | Phase 1, Phase 2 | Status: RECRUITING